Overview: Anti-Cyclic Citrullinated Peptide Antibody TestIntroduction: The Anti-Cyclic Citrullinated Peptide Antibody Test detects antibodies linked to rheumatoid arthritis, which causes joint pain, stiffness, or swelling. Aligned with 2023 ACR guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected rheumatoid arthritis.
Other Names: Anti-CCP Assay, Rheumatoid Arthritis Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Rheumatoid factor testing began in the 1940s. Anti-CCP assays emerged in the 1990s, and by the 2000s, high-sensitivity immunoassays improved specificity for rheumatoid arthritis.
Purpose: Diagnoses rheumatoid arthritis, guides treatment, and monitors disease activity in patients with joint pain, stiffness, or swelling.
Test Parameters: 1. Anti Cyclic Citrullinated Peptide
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like joint pain or swelling, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document joint symptoms, autoimmune disease history, or family history of rheumatoid arthritis. Include current medications, especially immunosuppressants or NSAIDs.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure anti-CCP antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm rheumatoid arthritis, prompting DMARD therapy. Negative results may require rheumatoid factor testing for confirmation.
Specialist Consultation: Consult a rheumatologist for result interpretation. An orthopedic specialist referral is advised for joint damage assessment.
Additional Supporting Tests: Rheumatoid factor test, ESR, or joint imaging to confirm rheumatoid arthritis or assess disease severity.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Results require clinical correlation.
References: ACR Rheumatoid Arthritis Guidelines, 2023; Arthritis and Rheumatology, Smolen JS, 2022.
